Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

452
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
452
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

506
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
506
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

856
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
856
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

788
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
788
Pneumonia IV: Management01:28

Pneumonia IV: Management

703
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
703

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Methodology and scope of peer-reviewed evaluations of TB programmes in high-incidence settings: a scoping review.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

Early interventions reduce multimorbidity and TB disability in Kenya, Uganda, Zambia, and Zimbabwe.

IJTLD open·2026
Same author

Operational research to End TB: 2<sup>nd</sup> edition of the Union's Guide to operational research.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Kartagener Syndrome: A First Report of Two Cases from Benin, West Africa.

West African journal of medicine·2025
Same author

Evaluating disability, comorbidities and risk factors after TB treatment: an 18-24 month follow-up.

IJTLD open·2025
Same author

TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe.

IJTLD open·2025
Same journal

A systematic review and meta-analysis of steroid use for treatment of TB meningitis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Accuracy of a fluorescent dye-qPCR for diagnosis of pulmonary TB in HIV-associated adults.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Incidence and predictors of TB infection among children and adolescents in the SONET study.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Attitudes towards adjunctive surgical therapy for pulmonary TB in Europe: an ESGMYC, ESTS, and TBnet collaborative survey.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same journal

Double trouble: enhancing integrated services for TB and diabetes.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
See all related articles

Related Experiment Video

Updated: Jan 3, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.9K

Should we consider a 'fourth 90' for tuberculosis?

A D Harries1, R A Dlodlo2, G Brigden2

  • 1International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease
|November 23, 2019
PubMed
Summary
This summary is machine-generated.

A proposed "fourth 90" target for tuberculosis (TB) aims to ensure 90% of patients completing treatment achieve good quality of life. This addresses lifelong comorbidities and disabilities impacting TB survivors

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.2K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.5K

Related Experiment Videos

Last Updated: Jan 3, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

2.9K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.2K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.5K

Area of Science:

  • Public Health
  • Infectious Diseases
  • Quality of Life Research

Background:

  • The global community aims to end tuberculosis (TB) by 2030, with targets set by the WHO's End TB Strategy.
  • The Stop TB Partnership established the 90-90-90 targets for TB diagnosis and treatment.
  • Successful TB treatment completion does not always equate to a good health-related quality of life for survivors.

Purpose of the Study:

  • To advocate for the inclusion of a "fourth 90" target focused on health-related quality of life for TB survivors.
  • To highlight the need for integrated care addressing comorbidities and disabilities post-TB treatment.
  • To align TB care with similar initiatives in HIV/AIDS management.

Main Methods:

  • Literature review and conceptual argument.
  • Analysis of existing TB treatment outcomes and patient-reported issues.
  • Comparative analysis with UNAIDS 90-90-90 targets.

Main Results:

  • Many individuals completing TB treatment experience persistent comorbidities (HIV, diabetes, lung disease) and disabilities (hearing loss, mental health disorders).
  • These long-term health issues often pre-exist or arise as a consequence of TB and its treatment.
  • A "fourth 90" target is proposed to ensure survivors achieve good quality of life.

Conclusions:

  • A "fourth 90" target is essential to address the comprehensive health needs of TB survivors.
  • Integrated, person- and family-centered care is crucial for managing lifelong comorbidities and disabilities.
  • Adopting this target would enhance TB and HIV programs, focusing on holistic patient recovery.